WSH Incorporates Drug Approval Dates from BioMedTracker for Pharma Traders
The dataset will provide all relevant and potentially market-moving event dates around drug trials and approvals.
The vendor rolled out the data into Enchilada as a "soft launch" earlier this month, following a beta test period in January with a few hedge funds and other clients to whom WSH provides XML feeds.
In addition to FDA PDUFA (Prescription Drug User Fee Act) dates, BioMedTracker also provides WSH with other relevant information, such as the date when a drug enters review by the FDA, expected approval date plus any changes to that expected date, and the final notice of approval or denial for both
Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.
To access these options, along with all other subscription benefits, please contact info@waterstechnology.com or view our subscription options here: http://subscriptions.waterstechnology.com/subscribe
You are currently unable to print this content. Please contact info@waterstechnology.com to find out more.
You are currently unable to copy this content. Please contact info@waterstechnology.com to find out more.
Copyright Infopro Digital Limited. All rights reserved.
As outlined in our terms and conditions, https://www.infopro-digital.com/terms-and-conditions/subscriptions/ (point 2.4), printing is limited to a single copy.
If you would like to purchase additional rights please email info@waterstechnology.com
Copyright Infopro Digital Limited. All rights reserved.
You may share this content using our article tools. As outlined in our terms and conditions, https://www.infopro-digital.com/terms-and-conditions/subscriptions/ (clause 2.4), an Authorised User may only make one copy of the materials for their own personal use. You must also comply with the restrictions in clause 2.5.
If you would like to purchase additional rights please email info@waterstechnology.com
More on Emerging Technologies
Moral models: The ethics of data management
The IMD Wrap: You may be managing data efficiently, but are you managing it ethically? And is that something you should be concerned about? Yes, says Max, you should.
The Waters Cooler: No Singapore Slings
Market microstructure, a prediction exchange, ETF and T+1 woes—does it get any more exciting than this?
Waters Wavelength Ep. 289: WFIC at Y’all Street
Nyela joins to talk about her time at WFIC this year.
Managing cloud costs comes down to putting controls in place
With cloud usage now pervasive throughout the capital markets, firms are focusing on stemming unintended costs.
Pledging the ledger: At the tipping point of blockchain networks that work together
Interest in distributed ledger technology (DLT) is gaining momentum, sparking lively debates among proponents and detractors. The key question is: which version of DLT is suitable for advancing financial markets—public/permissionless or private/permissioned networks?
The Waters Cooler: What is going on?
Is it weird that Euronext bought Substantive? It’s weird, right? Plus WFIC, tick sizes, Microsoft and BlackRock want more datacenters for some reason, and, of course, AI. What does it all mean?
Waters Wavelength Ep. 288: Media’s changing landscape
Wei-Shen and Tony discuss ways to improve the podcast going forward.
Fidelity’s quantum exploration unites theory and proof
The asset manager and Amazon have teamed to put a quantum twist on machine learning.
